Ground-breaking work creates novel oil-in-water nanoemulsions
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.
Particle Technology is an important discipline that underpins many industrial sectors, including biomedical applications, latex paints and coatings, engine oil additives, viscosity modifiers and emulsion stabilisation. Steve Armes, Professor of Polymer and Colloid Chemistry at the University of Sheffield, is one of the UK's leading experts in particle science and technology, with more than 30 years of research experience in this field. In particular, he designs a wide range of microscopic polymer particles on the nanoscale.
Professor Steve Armes said: "It is well known that oil and water do not mix. Similarly, the incorporation of oil droplets within inorganic crystals is highly counter-intuitive because there is a large difference in surface energy for these two components. Our new occlusion protocol, developed using the high-pressure LV-1 microfluidizer, has enabled either oil-soluble dyes or oil-dispersible hydrophobic nanoparticles to be incorporated for the first time within host crystals. This exciting new innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives for various commercial applications. In view of this, we have filed a preliminary patent application to protect the IP associated with our work.
Professor Ames added: “We are indebted to the excellent technical support provided by Analytik, which has enabled us to fully exploit the high-pressure LV-1 Microfluidizer for the production of well-defined nanoemulsions. We will be seeking their support and advice in the future as we seek to extend our studies to include water-in-oil nanoemulsions.”
The LV1 Microfluidizer is a high shear homogeniser which brings outstanding processing capabilities to samples as small as 1 mL. The LV1 has been designed to achieve operating pressures up to 30,000 psi for samples ranging from 1-6 mL. Using proprietary fixed-geometry interaction chamber technology, the LV1 is capable of processing a wide variety of fluids such as oil-in-water emulsions, solids-in-liquid suspensions, and cells, including the most difficult yeasts and plant cells, in as few as 1-2 passes. What's more, the process is repeatable and is guaranteed to scale up to pilot and/or production volumes.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance